Why four decades of intense research have yet to produce an HIV vaccine
In short: Since the AIDS epidemic began in 1981, over 40 million people have died, yet a vaccine remains elusive. The virus is a master of disguise, constantly shape-shifting to evade immune responses. While researchers are now leveraging mRNA technology and broadly neutralizing antibodies, the path to a viable vaccine remains complex.
The primary challenge in developing an HIV vaccine lies in the virus's inherent nature. Unlike many other pathogens, HIV is a shape-shifter that disguises itself to avoid detection. Early efforts focused on targeting the envelope protein, but the virus simply mutated to escape these antibodies. Researchers then pivoted to T cell-based approaches, hoping to kill infected cells. However, because HIV integrates its genetic material directly into the host's DNA, the immune system struggles to distinguish infected cells from healthy ones, rendering traditional vaccine platforms like live attenuated viruses too risky to use.
Furthermore, the virus exists in numerous subgroups, or clades, meaning a vaccine effective against one strain may fail against others. Even modern mRNA technology, which proved successful for COVID-19, faces hurdles here. While COVID-19 vaccines required the body to recognize a single spike protein, HIV may require a more complex response. Scientists are currently unsure how many viral proteins can be expressed via mRNA in a single vaccine, potentially limiting its efficacy against such a diverse pathogen.
Despite these setbacks, hope persists through the study of broadly neutralizing antibodies (bnAbs). Researchers at the NIH Vaccine Research Center have isolated these potent antibodies from long-term HIV patients. These antibodies can recognize various strains and clades, and scientists are now attempting to design a vaccine that teaches the human body to produce them naturally. While passive immunization trials using synthetic versions of these antibodies show promise, the requirement for repeated, ongoing administration remains a significant logistical barrier.
Public perception also complicates the mission. With the success of PrEP and antiretroviral therapies, many now view HIV as a manageable chronic condition rather than a life-threatening crisis. While these treatments are life-saving, they have shifted the urgency surrounding vaccine development. Experts like Anna Durbin note that while a vaccine is unlikely by 2030, the scientific community remains committed to the search, viewing current preventive treatments as a necessary bridge toward an eventual, permanent solution.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Why They Can't Make an HIV Vaccine (They're Trying!)
- Also: Why Don't We Have an HIV Vaccine? | Johns Hopkins Bloomberg School of Public Health
To cite this card, link to https://intellectplus.co.uk/app/science-why-they-can-t-make-an-hiv-vaccine-they-re-trying.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Vaccines · More in Health · Latest · A–Z · All topics